Schobel Alexander Mark
Known title: Chief Innovation/Tech OfficerCIK: 0001406836
Schobel Alexander Mark's purchase track record
Schobel Alexander Mark has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/8/2022 | AQST | $44K | +63.0% | -1.3% | -4.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AQST | ▼ Sell | Open Market | 50,000 | $300K | 3/15/2024 | View on chart |
| AQST | ▼ Sell | Tax Withholding | 5,895 | $29K | 3/9/2024 | View on chart |
| AQST | ▼ Sell | Open Market | 25,000 | $130K | 3/8/2024 | View on chart |
| AQST | ▲ Buy | Grant | 82,500 | $0 | 3/7/2024 | View on chart |
| AQST | ▲ Buy | Grant | 100,000 | $0 | 3/9/2023 | View on chart |
| AQST | ▲ Buy | Open Market | 45,871 | $44K | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Aquestive Therapeutics Appoints Richard Daly to Board
Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.
Aquestive Therapeutics Appoints Richard Daly to Board. Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.